https://www.selleckchem.com/products/jg98.html itoring standards as well as the systematic recording of complications when using PCIA are pending. Endovascular treatment (ET) in orally anticoagulated (OAC) patients has not been evaluated in randomized clinical trials and data regarding this issue are sparse. We analyzed data from the German Stroke Registry-Endovascular Treatment (GSR-ET; NCT03356392, date of registration 22 Nov 2017). The primary outcomes were successful reperfusion defined as modified thrombolysis in cerebral infarction (mTICI 2b-3), good outcome at 3months (modified Rankin scale [mRS] 0-2 or back to baseline), and intracranial hemorrhage (ICH) on follow-up imaging at 24h analyzed by unadjusted univariate and adjusted binary logistic regression analysis. Additionally, we analyzed mortality at 3months with adjusted binary logistic regression analysis. Out of 6173 patients, there were 1306 (21.2%) OAC patients, 479 (7.8%) with vitamin K antagonists (VKA) and 827 (13.4%) with non-vitamin K antagonist oral anticoagulation (NOAC). The control group consisted of 4867 (78.8%) non-OAC patients. ET efficacy with the rates of mTICI 2b-3 was similar among the three groups (85.6%, 85.3% vs 84.3%, p = 0.93 and 1). On day 90, good outcome was less frequent in OAC patients (27.8%, 27.9% vs 39.5%, p < 0.005 and < 0.005). OAC status was not associated with ICH at 24h (NOAC odd's ratio [OR] 0.89, 95% confidence interval [CI] 0.67-1.20; VKA OR 1.04, CI 0.75-1.46). Binary logistic regression analysis revealed no influence of OAC status on good outcome at 3months (NOAC OR 1.25, CI 0.99-1.59; VKA OR 1.18, CI 0.89-1.56) and mortality at 3months (NOAC OR 1.03, CI 0.81-1.30; VKA OR 1.04, CI 0.78-1.1.37). ET can be performed safely and successfully in LVO stroke patients treated with OAC. CLINICAL TRIAL REGISTRATION-URL http//www.clinicaltrials.gov . Unique identifier NCT03356392. ET can be performed safely and successfully in LVO stroke patients treated with OAC. CLINICAL